TSHA Share Price Performance
US$4.88
2.87 (142.79%)
48.2% undervalued intrinsic discount
US$9.42
Fair Value
Price US$4.88
AnalystConsensusTarget US$9.42
Fair ValueUS$9.42
Share PriceUS$4.88
48.2% undervalued intrinsic discount
Taysha Gene Therapies, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
TSHA Community Narratives
AN
Fair Value US$9.42 46.3% undervalued intrinsic discount
FDA Meetings And TSHA-102 Trials Will Advance Approval
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
Recent TSHA News & Updates
Taysha Gene Therapies, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.34
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,144.97%
- Debt/Equity Ratio
- 16.5%
Taysha Gene Therapies, Inc. Competitors
Snowflake Analysis
About TSHA
- Founded
- 2019
- Employees
- 73
- CEO
- WebsiteView website
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -2.8%
- 3 Months: 5.3%
- 1 Year: 13.4%
- Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a pullback of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›